Molecular pattern of ductal pancreatic cancer

被引:0
|
作者
V. Sirivatanauksorn
Y. Sirivatanauksorn
N. R. Lemoine
机构
[1] Molecular Pathology Laboratory,
[2] Imperial Cancer Research Fund Molecular Oncology Unit,undefined
[3] Imperial College School of Medicine,undefined
[4] Hammersmith Hospital,undefined
[5] London W12 ONN,undefined
[6] UK,undefined
[7] Division of Surgery,undefined
[8] Anaesthetics and Intensive Care,undefined
[9] Imperial College School of Medicine,undefined
[10] Hammersmith Hospital,undefined
[11] London W12 ONN,undefined
[12] UK,undefined
来源
关键词
Key words Pancreatic cancer; Oncogene; Tumour suppressor gene; Growth factors; Growth factor receptors;
D O I
暂无
中图分类号
学科分类号
摘要
Our understanding of the molecular pathology underlying the development and progression of ductal pancreatic cancer has been revolutionised during the last 5 years due to the spectacular development of novel molecular biological techniques. In the present article, we describe key molecular alterations of sporadic and inherited ductal pancreatic cancer. Overexpression of growth factors and growth factor receptors are present in a significant proportion of this tumour type. Mutation of the K-ras oncogene, and disruption of p53 or p16 tumour suppressor gene abrogates the control of the cyclin-dependent kinases (cdk) and retinoblastoma (Rb) gene pathway, causing continuous growth of the pancreatic tumour. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor β signalling pathway. Lost or decreased expression of retinoid receptors and failure of telomerase activity may play a role in pancreatic carcinogenesis. Tumour-associated proteinases, matrix metalloproteinases and plasminogen activators are reported to be involved in pancreatic cancer invasion and metastasis. Furthermore, the cytogenetic changes in this cancer are summarised. This molecular pattern distinguishes pancreatic cancer from other epithelial tumours and represents a promising basis for the development of diagnostic and other clinical applications.
引用
收藏
页码:105 / 115
页数:10
相关论文
共 50 条
  • [11] Prognostic factors in ductal pancreatic cancer
    C. J. Yeo
    J. L. Cameron
    Langenbeck's Archives of Surgery, 1998, 383 : 129 - 133
  • [12] Management of unresectable pancreatic ductal cancer
    Becker, J
    Bulkley, G
    Evans, D
    Geenen, JE
    Grendell, JH
    McLeod, R
    Nagorney, DM
    Venbrux, A
    JOURNAL OF GASTROINTESTINAL SURGERY, 1999, 3 (04) : 331 - 332
  • [13] Prognostic factors in ductal pancreatic cancer
    Yeo, CJ
    Cameron, JL
    LANGENBECKS ARCHIVES OF SURGERY, 1998, 383 (02) : 129 - 133
  • [14] The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
    Samuel, Nardin
    Hudson, Thomas J.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2012, 9 (02) : 77 - 87
  • [15] Molecular genetic alterations in ductal pancreatic adenocarcinomas
    Kern, SE
    MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (03) : 691 - +
  • [16] Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma
    Lee, Jaewon James
    Yeh, Jen Jen
    SURGICAL CLINICS OF NORTH AMERICA, 2024, 104 (05) : 939 - 950
  • [17] The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
    Nardin Samuel
    Thomas J. Hudson
    Nature Reviews Gastroenterology & Hepatology, 2012, 9 : 77 - 87
  • [18] The molecular genetics of pancreatic ductal carcinoma: a review
    Sohn, TA
    Yeo, CJ
    SURGICAL ONCOLOGY-OXFORD, 2000, 9 (03): : 95 - 101
  • [19] Short report - Lethal and aggressive pancreatic cancer: molecular pathogenesis, cellular heterogeneity, and biomarkers of pancreatic ductal adenocarcinoma
    Kannan, S.
    Ali, P. Shaik Syed
    Sheeza, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (03) : 1017 - 1019
  • [20] Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells
    Stoica, Andrei-Florian
    Chang, Chao-Hui
    Pauklin, Siim
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2020, 41 (12) : 977 - 993